Redcare Pharmacy's Margin Test Looms After a Prescription-Fueled Surge
Published on 04/20/2026 at 07:52 | Redaktion boerse-global.de
The spotlight is firmly on Redcare Pharmacy as the German online pharmacy giant prepares to unveil its full first-quarter financials. This report, due on May 6, will serve as the inaugural test for a newly installed management team tasked with proving that explosive sales growth can translate into sustainable profits.
Preliminary figures for Q1 2026 already set a high bar. Group revenue climbed 18.3% to €848 million, surpassing analyst expectations. The engine of this growth was the prescription business, where global sales surged 35%. In its core German market, the acceleration was even more dramatic, with prescription revenue exploding by 55% to €168 million. Even the historically slower over-the-counter segment showed renewed vigor, accelerating from 5.4% to 9.7% growth.
Yet, the company's stock tells a different story. Trading around €50.60, the share price sits far below its 200-day moving average and has shed roughly 25% since the start of the year. This disconnect highlights investor focus on the upcoming margin details. The interim statement will provide the first comprehensive look at profitability and cost structures under the watch of new CFO Hendrik Krampe. Krampe, officially confirmed at the annual meeting on April 15, brings over two decades of e-commerce expertise from tenures at Amazon and eBay.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
The company’s ambitious investment cycle is a key factor pressuring near-term margins. Redcare is constructing a new logistics center in Pilsen, which will increase annual capacity by 15 million parcels. This expansion has prompted a revision of the medium-term margin target from over 8% to more than 5%. For the current year, management has confirmed an adjusted EBITDA margin goal of at least 2.5%, with the investment ratio expected to fall below 2% of revenue after 2026.
A potential tailwind is brewing in Berlin. A government-appointed expert commission has recommended raising statutory co-payments for prescription drugs by 50%. Health Minister Nina Warken aims to advance the corresponding legislation swiftly. Analyst Felix Dennl of Bankhaus Metzler argues that higher out-of-pocket costs will drive price-sensitive patients toward more affordable online alternatives, a segment where Redcare commands a dominant 67% market share. This position was further solidified after competitor Rossmann confirmed it would not offer prescription medications.
Despite the stock's weakness, analyst sentiment remains bullish. Jefferies recently reaffirmed its "Buy" rating with a €150 price target, praising the strong start to the year. Deutsche Bank also recommends the equity, citing the growing market share in the e-prescription segment. The consensus price target among analysts stands near €95, nearly double the current trading level, with seven out of nine covering the stock advising clients to buy.
The May 6 report will reveal if the new leadership duo can deliver margins that match the impressive top-line momentum. For Redcare, the path from revenue champion to profitability leader is now under a microscope.
Ad
Redcare Pharmacy Stock: New Analysis - 20 April
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
